Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.
Combined treatment with pasireotide and pegvisomant has been shown to control disease in tumours with low somatostatin receptor (SSTR) subtype 2 expression, resistant to conventional somatostatin analogues (SSAs; alone or combined with pegvisomant) and to new-generation SSAs alone (pasireotide), reports a recent study.
Treatment with somatostatin analogues (SSAs) improves disease control in patients with acromegaly but reduces insulin levels, increases after-load glucose and increases glycated haemoglobin (HbA1c) levels without affecting fasting plasma glucose (FPG), suggests a recent study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Endocrinology - Malaysia digital copy today!